Showing 3131-3140 of 10546 results for "".
Analyzing IL-31 and the Benefits of Blocking It
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/analyzing-il-31-and-the-benefits-of-blocking-it/48777/James Q. Del Rosso, DO, FAOCD, discusses IL-31 and its involvement with itch, impairment of skin barrier function, and increased fibrosis of the skin.DermWireTV: New Data Presented for Atopic Dermatitis and Prurigo Nodularis Candidates at AAD
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-new-data-presented-for-atopic-dermatitis-and-prurigo-nodularis-candidates-at-aad/24127/In this episode of DermWireTV, a phase 3 study finds roflumilast cream is associated with significantly improved atopic dermatitis in children; first-of-its-kind research suggests that eczema treatment lebrikizumab shows efficacy and safety in patients with skin of color; and new data reveals oral JDermWireTV: Medicare Cuts; Revision, Alastin, Obagi Acquisitions; CSF Hits Nashville
https://practicaldermatology.com/topics/practice-management/dermwiretv-medicare-cuts-revision-alastin-obagi-acquisitions-csf-hits-nashville/20033/Congress is working to avert a potential pay cut for physicians who treat Medicare patients, and a bipartisan solution has been introduced. Cuts loom as the AMA has released data showing that Medicare claims data exclusive to physician services fell an estimated $13.9 billion or 14 percent below exp2018 Therapeutics and Device Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2018-therapeutics-and-device-highlights/18374/2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.Telemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse andBONT-A Extends Fillers; Almirall to Acquire Thermi
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-bont-a-extends-fillers-almirall-to-acquire-thermi/18648/In this edition of DermWireTV, a look at new data showing that injections with botulinum neurotoxin can extend the efficacy of hyaluronic acid fillers. The American Academy of Dermatology Association offers more response to the USPSTF draft recommendation on the benefits of skin exams for melanoma.Online Reputation Management Update
https://practicaldermatology.com/topics/practice-management/online-reputation-management-update/18658/Protecting your online reputation is crucial to your digital marketing success. If you think it's all about spotting and hiding bad reviews, you're wrong. Learn how to build and protect a stellar online reputation for your dermatology practice and how it will actually boost SEO. The Ekwa Marketing tDWTV Extra: Vitiligo Ingenuity Award
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-vitiligo-ingenuity-award/37869/Hannah Metheny, a student at the University of Miami Miller School of Medicine, discusses winning an Incyte Ingenuity Award in Vitiligo for the "Barriers and Facilitators to Psychosocial Support as an Integral Aspect of Vitiligo Patient Comprehensive Care" project.DermWireTV: Dermatologists React to the Valisure Report; FDA Approves New Treatment for Frown Lines
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermatologists-react-valisure-report-fda-approves-new-treatment-frown-lines/24157/In this episode of DermWireTV, dermatologists react to the recent Valisure report that found elevated levels of benzene when studied under laboratory conditions in certain acne products containing BPO; the FDA approves a new treatment option for glabellar lines; and the PA Perspectives series addresDermWireTV: AAD Virtual Data Highlights, Cynosure Consumer Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aad-virtual-data-highlights-cynosure-consumer-data/19818/The American Academy of Dermatology 2020 VMX Virtual Conference shines a light on fresh data from UCB, Leo Pharma, Lilly and Dermira, and Soliton. Cassiopea reports long-term data for Clascoterone. Zilxi from Menlo and Foamix approved for rosacea. Cynosure reports positive cosmetic consumer outlook